Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended versus intermittent meropenem infusion in pediatric febrile neutropenia
IRCT20120731010453N8Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meropenem in febrile neutropenia (FN) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Serum meropenem levels, Mortality and 2 more. Started Nov 2025; status: completed.
02
Drugs
meropenem
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on IRCT20120731010453N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120731010453N8.